Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC 40.5 × 10e9/L and transfusion independent plt count 420 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC 40.5 × 10e9/L at 30 days was 87% and transfusion independent plt count 420 × 10e9/L at 100 days was 87%. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9-38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0-12.4%). The median followup is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients. 1-5 HDC is also effective for relapsed chemosensitive follicular non-Hodgkin lymphoma. 6 However, this leaves a substantial number of patients who need further therapy because of relapse after HDC. In this setting, after the initial disappointing results achieved with myeloablative regimens due to a high non-relapse mortality rate, the use of allo-hematopoietic SCT (allo-HSCT) has grown with the development of reduced intensity conditioning or truly non-myeloablative conditioning (NMAC) regimens. Several studies have established the feasibility of reduced intensity conditioning/NMAC, but the long-term progression-free survival remains unsatisfactory due to excessive post-transplantation relapse deserving further developments.
INTRODUCTION
Most patients with Hodgkin lymphoma and aggressive lymphomas are cured with first line chemotherapy while almost one half with relapsed or progressive disease, who respond to salvage chemotherapy, are cured by high dose chemotherapy (HDC) with autologous stem cell. [1] [2] [3] [4] [5] HDC is also effective for relapsed chemosensitive follicular non-Hodgkin lymphoma. 6 However, this leaves a substantial number of patients who need further therapy because of relapse after HDC. In this setting, after the initial disappointing results achieved with myeloablative regimens due to a high non-relapse mortality rate, the use of allo-hematopoietic SCT (allo-HSCT) has grown with the development of reduced intensity conditioning or truly non-myeloablative conditioning (NMAC) regimens. Several studies have established the feasibility of reduced intensity conditioning/NMAC, but the long-term progression-free survival remains unsatisfactory due to excessive post-transplantation relapse deserving further developments. [7] [8] [9] [10] [11] [12] [13] [14] [15] Another limitation to the use allo-HSCT in a salvage strategy is the availability of donors: half of the Caucasian patients are able to find a HLA-identical sibling or matched unrelated donor (MUD), this percentage being even lower in ethnic minorities. Alternative non-identical stem cells sources such as cord blood or haploidentical-related donors have the potential to expand the accessibility to allo-HSCT for these patients. Encouraging results have been obtained with a novel approach of using haploidentical-related donors, NMAC, T-repleted bone marrow and post-transplant high dose CY (pT-HDCy) in patients with advanced hematological malignancies. 16 pT-HDCy administered early at a fixed time point after bone marrow infusion, has shown to eradicate allo-reactive donor and host T cells, activated by respective Ags, thereby reducing the incidence of GVHD and host vs graft reaction (HVG). 17 It has been shown that pT-HDCy does not affect the engraftment potential due to the enzymatic resistance to this agent of hematopoietic stem cells. 18 The aim of this study was to report the results of haploidentical transplantation in a cohort of advanced lymphoma patients treated in two collaborative institutions, assessing toxicity and feasibility of this approach.
PATIENTS AND METHODS
From April 2009 to September 2012, 49 advanced lymphoma patients underwent haploidentical transplantation in two institutions. This retrospective study was approved by IRB (ONC/OSS-04/2013) and conducted in accordance with the Helsinki declaration.
Patients received transplantation from a related haploidentical donor with NMAC and pT-HDCY, if a HLA identical or MUD was unavailable, if they had relapse/progression after a previous HDC or allogeneic SCT or if they were unresponsive to several line salvage chemotherapies. Patients' refractory to conventional salvage chemotherapy received an HDC with autologous stem cells support and thereafter they underwent haploidentical transplantation. HDC consisted of melphalan (200 mg/m day − 1. GVHD prophylaxis consisted of Cy 50 mg/kg given on days +3 and +4, tacrolimus or CsA and mycophenolate mofetil. Tacrolimus (FK) was administered at 1 mg total dose, as a continuous infusion until discharge, and converted to oral formulation therafter. The doses were adjusted to obtain serum levels between 10 and 20 ng/mL. CsA was dosed at 3 mg/kg as a continuous infusion until discharge, and converted to oral formulation thereafter. The doses were modified to obtain serum levels between 100 and 200 ng/mL. Mycophenolate mofetil was administered at a rate of 15 mg/kg 3 per day, until day +35 and then stopped. FK, CsA and Mycophenolate mofetil were started at day +5. FK and CsA were tapered by day 180. G-CSF was started at day +5 in all patients.
Acute was graded according to Keystone criteria 20 and chronic GVHD (cGVHD) was graded following the NIH criteria. 21 Potential family members were typed at the HLA-A, HLA-B and HLA-DRB1 loci at an intermediate resolution level. Donors selected were typed at the HLA-C locus at an intermediate resolution level. DRB1 and DQB1 alleles were typed at a high-resolution level. All donor/recipient pairs displayed two to three differences on the unshared haplotype. Donors underwent bone marrow harvest under general anaesthesia with a collection target of 4 × 10 8 nuclear cells. Unmanipulated bone marrow was infused on day 0. In Institut Paoli Calmettes, 10 donors were mobilized with filgrastim for 5 to 6 days (Neupogen, 10 mcg/kg/day) for PBSC collection.
Antimicrobial prophylaxis and monitoring infections were applied as per center guidelines. Toxicity was evaluated following the National Cancer Institute-Common Toxicity Criteria scale.
Clinical and demographical characteristics were summarized as number and percentage or as median and range, and differences between groups were evaluated by continuity adjusted χ 2 -test or the Fisher's exact test when appropriated.
Survival analysis was performed by plotting survival curves according to the Kaplan-Meier method. The study population was stratified for principal clinical and demographical characteristics and groups were compared by means of the log rank test. Cumulative incidence was considered to estimate plt recovery, ANC recovery, aGVHD, cGVHD, relapse/progression incidence and non relapse mortality after haploidentical transplantation. Cox proportional hazards model was applied to evaluate hazard ratio with corresponding 95% confidence interval (95% CI). A P-value o 0.05 was considered to be the limit of statistical significance. Table 1 . All patients received a median of three conventional chemotherapy (CT) lines, and 27 (55%) had a relapse after HDC and seven (14%) after allogeneic transplantation. Nine patients (18%) who were refractory to salvage CT were treated in an auto-allo program, consisting of a HDC with melphalan (200 mg/m 2 ) plus auto-PBSC, and after a median time of 53 days (40-91) they received haploidentical transplantation. Twelve out the 17 non-Hodgkin lymphoma patients (71%) had aggressive histology.
RESULTS

Patient characteristics are reported in
Thirty-nine patients received unmanipulated bone marrow stem cells and the median number of TNC and CD34+ cells infused were 3.7 × 10e8/kg (range 0.8-4.8) and 3.3 × 10e6/kg (range 1.4-5.5), respectively. Ten patients (all in Institut Paoli Calmettes) received GCSF-mobilized PBSC and the median number of CD34+ cells were 5.1 × 10e6/kg (range 3.9-10.8), significantly higher than bone marrow (P 0.001). Forty-six (94%) patients were evaluable for hematological recovery as one patient died on day +9 and two had primary graft failure. Both graft failures were related to the presence of donor-specific Ab in the patients (both against class I and II). Both patients were infused with back up autologous stem cells, and they were alive in CR at the time of this report. For engrafted patients, median time for ANC recovery more than 0.5 × 10e9/L and transfusion-independent plt count more than 20 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395), respectively. The probability to reach ANC more than 0.5 × 10e9/L at 30 days was 87% and transfusion independent plt count more than 20 × 10e9/L at 100 days was 87% (Figure 1 ). There was no statistical difference in terms of ANC, and plt engraftment between PBSC and bone marrow populations. Donor chimerism was studied only in 44 patients due to early death (N = 3) and graft failure (N = 2). The median time to obtain full donor chimerism was 35 days (17-211).
All subjects received transplantation as in-patient. Conditioning regimens were well-tolerated and no grade 3-4 mucositis was observed. The median time of discharge from the hospital was 34 days (range 19-111). Infectious complications were analysed excluding patients with graft failure. Viral, bacterial and fungal infections were observed in 59%, 44% and 12% of patients, respectively. The median time for bacterial, viral and fungal infections were 14 days (range 4-316), 46 days (range 5-354) and 22 days (range 1-62), respectively.
CMV reactivation occurred in 29%, and two CMV-related diseases were diagnosed. EBV DNAemia was detected in 10% of the patients, but no EBV-related disease was observed. Cystitis due Haplo transplantation for lymphomas L Castagna et al to BK virus was observed in 8% of the patients. Other less frequent viral infections were H1N1 pneumonia (one patient), respiratory syncytial virus rhinitis (one patient), respiratory syncytial virus pneumonia (one patient), HHV-6 pneumonia (one patient) and PML due to JC virus (one patient). Gram negative or positive septicemia was detected in 28% of the patients (gram negative: 22% and gram positive: 6%). Pneumonia was observed in 30% of the patients, and it was documented in 50% of them (eight bacterial, four viral and two fungal). Invasive fungal infection incidence was 12% (invasive aspergillosis 8% and disseminated candidemia 4%).
Patients with acute GVHD (aGVHD) did not develop more infections than patients without aGVHD, except for CMV reactivations (58 vs 17%, P 0.024) ( Table 2) .
Forty-seven patients (96%) were evaluable for aGVHD. Ten patients developed cutaneous grade 2 aGVHD and two patients grade IV liver aGVHD. The cumulative incidence of grades 2-4 aGVHD were 25.6% (95% CI: 12.9-38.3%). The median time to grade 2-4 aGVHD was 44 days (range 25-81).
Forty patients (82%) were evaluable for cGVHD and the cumulative incidence of cGVHD (all moderate) was 5.2% (95% CI: 0-12.4%).
The median follow-up for surviving patients was 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71% and 63%, respectively (Figure 2) .
Univariate analysis for factors influencing PFS and OS were performed (Table 3) . Histology (HL vs non-Hodgkin lymphoma) impacted significantly the OS (87 vs 54%, P-value 0.02) but not the PFS (76 vs 56%, P-value 0.167). The hazard ratio of non-Hodgkin lymphoma vs HL was 3.8 (95% CI: 1.1-12.6, P-value 0.02).
The overall cumulative relapse/progression incidence was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse/ progression was 4.4 months (range 1.1-8.3) .
At last follow-up, 13 patients have died: seven deaths were treatment related and six were due to lymphoma relapse. At 2 years, the cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%) (Figure 3) . The causes of transplant-related death were H1N1 diffuse interstitial pneumonia, JC-related PML, gramnegative septic shock, liver failure, CMV pneumonia, VRS pneumonia and invasive aspergillosis.
DISCUSSION
This study confirms the feasibility of performing haploidentical T-cell repleted SCT using a NMAC and pT-HDCy as originally reported by the Johns Hopkins group. Indeed, in our series of patients with lymphoma, mortality rate was low and not different from mortality reported after allo-HSCT using familiar or unrelated HLA identical donor. 22 Severe GVHD and a high incidence of HVG reactions have been the major problems encountered when haploidentical donors, without T-cell depletion, have been used after myeloablative regimen. 23 Haploidentical platforms with T-cell depletion, with different strategies have been published, but, beside the complexity, reproducibility and cost of the procedures, results were impaired by infectious complications and high rate of relapse. [24] [25] [26] [27] More recently, in patients lacking a HLA identical, Luznik et al. 16 reported on donor T-cell repleted haploidentical transplantation with encouraging results and a promising safety profile. Engraftment was high, as only two patients had graft failure. The median time for a safe ANC was slightly longer in our patients compared with the study by Luznik et al. 16 (median 20 days vs 15 days), which could be linked to lower number of CD34+ cells infused and/or to differences in patient selection. Furthermore, GCSF was started at day +5 in our cohorts instead of day +1. Plt count recovery was similar (26 vs 28 days). In our cohort, 10 patients received PBSC but the median number of days to engraft was similar to patients grafted with bone marrow.
The incidence of aGVHD was acceptable considering that we observed only two grade IV liver aGVHD, while all other patients developed aGVHD limited to the skin. Moderate cGVHD was observed only in 5% of the patients. Overall, these results support the view that pT-HDCy induces a profound immunosuppressive effect, thus allowing donor engraftment and low GVHD incidence.
Two patients had HVG reaction mediated by donor-specific Ab, as previously reported. 28 One of these patients received a desensitization treatment with Rituximab, high-dose Ig and several plasma exchanges, and infusion of CD34 selected peripheral stem cells from the same donor with ATG (5 mg/kg). Donor-specific Ab did not disappear and she failed to engraft.
The major concern in the study by Luznik et al. 16 was a high relapse rate (58% at 2 year). This was likely linked to disease characteristics, but the impact of the procedure, including conditioning, GVHD prophylaxis and donor origin, could be invoked. In our series of patients, relapse rate was lower (18%), but population was different: we did not include myeloid malignancies or ALL, which seemed to relapse more than lymphoproliferative diseases. 29 Furthermore, in our cohort, most of the patients had HL, which seemed particularly sensitive to alloreactivity after haploidentical transplantation as also reported by Bourroughs et al. in a retrospective comparison with HLA identical transplantation from sibling or MUDs. 30 Furthermore, in univariate analysis, the only factor predictive of outcome was the histology with higher PFS and OS for HL. The results observed in the HL patients are particularly appealing because in most studies reporting on allogeneic transplantation using a matched donor, the PFS, OS and NRM were 25-30%, 50-60% and 15-30%, respectively. 22 The dark side of an effective protection from GVHD/HVG reaction is the slow recovery of immune system. 24 In mice studies, Cy killed activated T cells (both in the GVH and HVG direction) sparing T cells not reacting against host or donor Ags, which contained T cells with immunity to infections and effective in producing long term immune reconstitution. In line with animal data, Luznik et al. 16 reported a low incidence of infectious complications (38% and 7% of the patients had CMV reactivation and fungal infections, respectively). In our cohort, we observed mainly viral complications. The CMV reactivation incidence was similar (29%), and other viruses such as EBV (10%) or polyoma virus infection (8% as BK cystitis) were frequently identified. However, only two CMV-related diseases were observed, with no EBV-related lymphoproliferative disorders. Invasive fungal infection incidence was quite low.
Tuve et al. 11 published data on 18 patients, with acute leukemia and different lymphoma histotypes, receiving haploidentical transplantation and Cy post transplant. Eleven patients received the Baltimore protocol and seven were conditioned with different conditioning regimens. The outcome was encouraging for poor prognosis patients with 1-year OS, PFS and NRM of 94%, 86% and 5%, respectively. aGVHD and cGVHD incidence was 29% and 35%, respectively, (limited only). Globally, this study also confirmed the feasibility of post-transplantation Cy in the haploidentical context. 31 The results obtained in this small series seem to compare favourably with other reports, as shown in some selected papers (Table 4) , where the majority of donors were HLA identical siblings or MUDs. Although the outcomes varied significantly based on some variables such as histology, disease status and age, the results obtained in the present series are encouraging.
These data invite consideration of haploidentical transplantation as an affordable choice in lymphoma patients, eligible for allogeneic transplantation but without a HLA identical donor, with special consideration for patients with HL when a HLA identical sibling and a MUD are not available or not found in the right time. Considering that NRM is not so different from more conventional stem cell sources but lower than alternative donors such as cord blood 32 and mismatched unrelated donors 33, 34 and OS seems higher, a haploidentical donor should be taken into account.
In conclusion, haploidentical transplantation with NMA and post-transplantation CY as GVHD/HVG prophylaxis seemed to be safe and feasible in poor prognosis lymphoma patients. In this setting, we are starting a prospective phase II multicenter study testing a more active conditioning regimen to improve the outcome. Furthermore, an extensive evaluation of immune reconstitution is ongoing to obtain detailed data and consequently to establish a strong platform to test specific immunotherapy after transplantation. 
